中国中医药信息杂志2016，Vol.23Issue(3)：126-128,129,4.DOI:10.3969/j.issn.1005-5304.2016.03.038
中药改善肺癌靶向治疗表皮生长因子受体酪氨酸激酶抑制剂获得性耐药研究进展
Research Progress in Ameliorating EGFR-TKIs Acquired Resistance of Targeted Therapy in Lung Cancer by Traditional Chinese Medicine
摘要
Abstract
Acquired resistance of EGFR-TKIs has become the major limitation of the efficacy of targeted therapy for lung cancer. Lung cancer has been treated by traditional Chinese medicine (TCM) combined with EGFR-TKIs, which originated from clinic. In recent years, reversing research has been conducted based on clinic application to discuss TCM intervening, improving and reversing EGFR-TKIs acquired resistance becoming a novel target for research. This article reviewed mechanism and effects of TCM herbs and compounds’ with the efficacy of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis strengthening the body resistance, and invigorating the circulation of blood, and proposed that the whole regulation and targeted therapy of TCM may carry out synergistic effect and become innovation treatment model for lung cancer.关键词
表皮生长因子受体酪氨酸激酶抑制剂/获得性耐药/中药/靶向治疗/综述Key words
EGFR-TKI/acquired resistance/traditional Chinese medicine/targeted therapy/review分类
医药卫生引用本文复制引用
刘浩..中药改善肺癌靶向治疗表皮生长因子受体酪氨酸激酶抑制剂获得性耐药研究进展[J].中国中医药信息杂志,2016,23(3):126-128,129,4.基金项目
国家自然科学基金（81573950）；北京市自然科学基金 （）
